Jonik Szymon, Piasecki Adam, Jastrzębska Anna, Opolski Grzegorz, Grabowski Marcin, Huczek Zenon, Kochman Janusz
1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Med Sci Monit. 2025 Jun 26;31:e948348. doi: 10.12659/MSM.948348.
BACKGROUND Many randomized controlled trials have explored the optimal revascularization strategy for patients with diabetes, but real-life outcomes are still poorly investigated. We assessed the complete 6-year outcomes of diabetic individuals with multivessel coronary artery disease (MVD) treated either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). MATERIAL AND METHODS We reviewed data of all patients from 176 local Heart Team meetings and their treatment recommendations and assessed primary and secondary endpoints of 317 MVD patients with diabetes qualified either for CABG or PCI (98 and 219 patients, respectively) with subsequent optimal medical therapy. RESULTS At 6 years, no significant difference in overall mortality was observed (16.3% vs 20.5% for PCI, P=0.38). The incidence of myocardial infarction (MI) was higher in patients treated percutaneously (4.1% vs 12.3% for PCI, P=0.02), while those undergoing CABG had significantly longer postprocedural hospital stay (10.7 vs 4.4 days for PCI, P<0.01). The occurrence of major adverse cardiac and cerebrovascular events (MACCE), mainly driven by the increased rate of repeat revascularization (RR), was higher in the PCI group (83.6% vs 44.9%, P<0.01 and 47.0% vs 17.3%, P<0.01, respectively). The rates of stroke and in-hospital mortality were similar between the 2 groups. CONCLUSIONS For MVD patients with diabetes, CABG was superior in real-life clinical practice in terms of rates of MI, RR, and MACCE, while postprocedural hospital stays were shorted with PCI. The rates of all-cause death, stroke, and in-hospital mortality were comparable between groups.
背景 许多随机对照试验探讨了糖尿病患者的最佳血运重建策略,但对实际治疗效果的研究仍较少。我们评估了多支冠状动脉疾病(MVD)的糖尿病患者接受冠状动脉旁路移植术(CABG)或经皮冠状动脉介入治疗(PCI)后的6年完整治疗效果。
材料与方法 我们回顾了176次当地心脏团队会议中所有患者的数据及其治疗建议,并评估了317例符合CABG或PCI标准(分别为98例和219例患者)的MVD糖尿病患者在接受后续最佳药物治疗后的主要和次要终点。
结果 6年后,总体死亡率无显著差异(PCI组为16.3%,CABG组为20.5%,P = 0.38)。接受PCI治疗的患者心肌梗死(MI)发生率更高(PCI组为4.1%,CABG组为12.3%,P = 0.02),而接受CABG治疗的患者术后住院时间明显更长(PCI组为4.4天,CABG组为10.7天,P < 0.01)。PCI组主要由重复血运重建率(RR)增加导致的主要不良心脑血管事件(MACCE)发生率更高(分别为83.6%对44.9%,P < 0.01和47.0%对17.3%,P < 0.01)。两组之间的中风和住院死亡率相似。
结论 对于患有MVD的糖尿病患者,在实际临床实践中,就MI、RR和MACCE发生率而言,CABG更具优势,而PCI术后住院时间更短。两组之间的全因死亡率、中风和住院死亡率相当。